Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine

Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D portfolios Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D portfolios

BullFrog to Host Webinar on New Precision AI Capability

March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI's new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI's new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design

BullFrog AI to Unveil New Precision AI Capability

GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design.

BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer

Company's bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI Company's bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI